Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals ( REGN ). Our analysis of options history for Regeneron Pharmaceuticals ( REGN ) revealed 14 unusual trades.

Delving into the details, we found 14% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $721,270, and 10 were calls, valued at $1,045,138.

Projected Price Targets

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $960.0 to $1280.0 for Regeneron Pharmaceuticals ( REGN ) over the last 3 months.

Analyzing Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Regeneron Pharmaceuticals's ( REGN ) options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Regeneron Pharmaceuticals's ( REGN ) significant trades, within a strike price range of $960.0 to $1280.0, over the past month.

Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days

Significant Options Trades Detected:

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals ( REGN ) discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Following our analysis of the options activities associated with Regeneron Pharmaceuticals ( REGN ), we pivot to a closer look at the company's own performance.

Where Is Regeneron Pharmaceuticals Standing Right Now?

With a trading volume of 322,187, the price of REGN is down by 0.0%, reaching $1063.89.

Current RSI values indicate that the stock is may be overbought.

Next earnings report is scheduled for 37 days from now.

What The Experts Say On Regeneron Pharmaceuticals

A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1195.6.

An analyst from JP Morgan has decided to maintain their Overweight rating on Regeneron Pharmaceuticals ( REGN ), which currently sits at a price target of $1150.

Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Regeneron Pharmaceuticals ( REGN ), targeting a price of $1200.

An analyst from RBC Capital downgraded its action to Outperform with a price target of $1229.

An analyst from Argus Research persists with their Buy rating on Regeneron Pharmaceuticals ( REGN ), maintaining a target price of $1170.

Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Regeneron Pharmaceuticals ( REGN ) with a target price of $1229.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals ( REGN ) options trades with real-time alerts from Benzinga Pro.